Clincosm LogoSign in Get a demo

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

Sponsor
MedImmune LLC (Industry)
Overall Status
Completed
CT.gov ID
NCT00299819
Collaborator
(none)
45
Enrollment
21
Locations
5
Arms
19
Duration (Months)
2.1
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients with SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of another oral corticosteroid.

Condition or Disease Intervention/Treatment Phase
  • Biological: MEDI-545
  • Biological: MEDI 545
  • Biological: MEDI-545
  • Biological: MEDI-545
  • Biological: MEDI-545
 Phase 1

Detailed Description

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients who have SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of another oral corticosteroid.

The secondary objective of this study is to describe the pharmacokinetics and potential immunogenicity of MEDI-545.

Study Design

Study Type:
Interventional
Actual Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients With Systemic Lupus Erythematosus (SLE)
Study Start Date :
Mar 1, 2006
Actual Study Completion Date :
Oct 1, 2007

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 1

MEDI-545

Biological: MEDI 545
0.3 mg/kg IV (n=6) at Study Day 0
Active Comparator: 2

MEDI-545

Biological: MEDI-545
0.3 mg/kg IV (n=6) at Study Day 0
Active Comparator: 3

MEDI-545

Biological: MEDI-545
0.3 mg/kg IV (n=6) at Study Day 0
Active Comparator: 4

MEDI-545

Biological: MEDI-545
0.3 mg/kg IV (n=6) at Study Day 0
Active Comparator: 5

MEDI-545

Biological: MEDI-545
0.3 mg/kg IV (n=6) at Study Day 0

Outcome Measures

Primary Outcome Measures

  1. Safety and tolerability of MEDI-545 will be assessed primarily by summarizing adverse events. [Day 84]

Secondary Outcome Measures

  1. Evaluation of MEDI-545 pharmacokinetics and possible immunogenicity [Day 84]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Patients must meet all of the following criteria:

  • Adult males and females ≥ 18 years at the time of the first dose of study drug.

  • Written informed consent obtained from the patient/patient's legal guardian

  • Diagnosis of SLE: Patients must have previously met ≥ 4 of the 11 revised ACR criteria

  • Current background treatments may include the following medications prior to randomization: acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and antimalarials, such as hydroxychloroquine ≤ 600 mg/day, and prednisone ≤ 20 mg daily (or an equivalent dose of another oral corticosteroid) for at least 28 days

  • Sexually active females, unless surgically sterile or at least two years post-menopausal, must use an effective method of avoiding pregnancy (including oral, injectable, transdermal, or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 28 days before the first dose of study drug, and must agree to continue using such precautions through the study period of 84 days. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active males, unless surgically sterile, must likewise use an effective method of birth control (condom or abstinence) and must agree to continue using such precautions through Study Day 84.

  • Ability to complete follow-up period of 84 days as required by the protocol.

Exclusion Criteria:

  • Weight ≥ 120 kg

  • Use of cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil or cyclosporine within 28 days before study entry

  • Use of doses of corticosteroids higher than the equivalent of prednisone 20 mg/day (or an equivalent dose of another corticosteroid) within 28 days before study entry

  • In the opinion of the investigator, a likelihood of requiring initiation of immunosuppressant therapy (e.g., prednisone >20 mg daily (or an equivalent dose of another oral corticosteroid), azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, or dapsone) within the 28 days after study entry. Antimalarial dosing must be held constant during the study, but analgesics and NSAIDs may be varied.

  • Current treatment with coumadin

  • Treatment with immunoglobulin or blood products within 28 days before entry into the study

  • Treatment with any investigational drug therapy within 28 days before entry into the study; in the case of cell-depleting therapies, such as B or T cell depletion, cell counts that remain below acceptable or baseline levels (use of licensed agents for indications not listed in the package insert is permitted)

  • History of primary immunodeficiency

  • History of allergic reactions likely to be exacerbated by any component of the study drug

  • Previous medical history, or evidence, of an intercurrent illness, other than SLE, that may compromise the safety of the patient in the study

  • Clinically significant cardiac disease, including: unstable angina; myocardial infarction within 6 months; congestive heart failure; arrhythmia requiring active therapy, with the exception of clinically insignificant extra systoles, or minor conduction abnormalities; and history of clinically significant abnormality on electrocardiogram

  • Evidence of significant active infection, or vaccination with live attenuated viruses, currently or in the 2 weeks before randomization

  • Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening

  • A history of severe infection with viruses of the herpes family including Epstein-Barr virus requiring hospitalization, disseminated herpes, herpes encephalitis, ophthalmic herpes, or cytomegalovirus

  • Herpes zoster ≤ 3 months prior to screening

  • Current suppressive antiviral therapy for herpes or other viral infections

  • Ongoing, chronic infectious disease such as chronic renal infection or chronic chest infection with bronchiectasis or sinusitis

  • Pregnancy (females, unless surgically sterile or at least two years post-menopausal must have a negative serum pregnancy test within 14 days before receiving the study drug and a negative urine pregnancy test on Study Day 0 before receiving the study drug)

  • Nursing mother

  • History of alcohol or drug abuse within the past 2 years

  • Presence of end-stage renal disease, or rapidly progressive glomerulonephritis

  • Active central nervous system lupus

  • History of stroke, or any cerebrovascular disease requiring medication/treatment.

  • History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >1 year prior to enrollment

  • At screening (must be within14 days before entry into the study) any of the following:

  • AST > 1.5x upper limit of normal range (ULN)

  • ALT > 1.5x ULN

  • creatinine > 1.5x ULN for patient's age, sex and weight

  • serum K above or below the normal range

  • hemoglobin < 8 g/dL

  • white blood cell count < 1,800/mm3 (Superscript)

  • neutrophils < 1,500/mm3 (Superscript)

  • platelet count < 50,000/mm3 (Superscript)

  • other abnormal laboratory values in the screening panel that in the opinion of the principal investigator are judged to potentially confound analysis of study results

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pinnacle Research Group Anniston Alabama United States 35207
2 Wallace Rheumatic Study Center Los Angeles California United States 90048
3 Clinical Research of West Florida Clearwater Florida United States 33765
4 Center for Rhematology, Immunology, and Arthritis Ft. Lauderdale Florida United States 03334
5 Ocala Rheumatology Research Center Ocala Florida United States 34474
6 Tampa Florida Medical Research Group Tampa Florida United States 33614
7 Florida Medical Clinic, Clinical Research Division Zephyrhills Florida United States 33542
8 Louisiana State University Health Sciences Center-Shreveport Shreveport Louisiana United States 71130
9 Johns Hopkins University, School of Medicine Baltimore Maryland United States 21205
10 St. Mary's Duluth Clinic Duluth Minnesota United States 55805
11 Hospital for Special Surgery New York New York United States 10021
12 Columbia University Medical Center New York New York United States 10032
13 Oklahoma Medical Research Foundation Oklahoma City Oklahoma United States 73104
14 Oregon Medical Research Center Portland Oregon United States 97223
15 Altoona Center for Clinical Research Duncansville Pennsylvania United States 16635
16 University of Texas Southwestern Medical Center Dallas Texas United States 75390
17 University of Washington Div. of Rhematology Seattle Washington United States 98195
18 Center for Innovative Therapy, UCSD School of Medicine Milwaukee Wisconsin United States 53226
19 Froedtert Hospital, Medical College of Wisconsin Milwaukee Wisconsin United States 53226
20 Toronto Western Hospital Toronto Ontario Canada MST 258
21 Montreal General Hospital Montreal Quebec Canada H3G 1A4

Sponsors and Collaborators

  • MedImmune LLC

Investigators

  • Study Director: Barbara White, M.D., MedImmune LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00299819
Other Study ID Numbers:
  • MI-CP126
  • NCT00394719
First Posted:
Mar 7, 2006
Last Update Posted:
Dec 18, 2007
Last Verified:
Dec 1, 2007
Keywords provided by , ,
Lupus
Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Sifalimumab
Antibodies, Monoclonal

Study Results

No Results Posted as of Dec 18, 2007